Project Grant R01AR083939
Award Date
7/5/25
Completion Date
6/30/30
Dollars Obligated
$413K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $1,150,474 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to explore the cellular and molecular mechanisms driving large-scale bone regeneration. The research aims to unravel the intricate events necessary for extensive bone repair by investigating the role of a sentinel-type cell population marked by SOX9 expression in...
The University of Texas Southwestern Medical Center (UT Southwestern) received a $312,871 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The award, effective May 1, 2025 through April 30, 2030, supports the development of a novel pro-angiogenic bone coating hydrogel (ABC hydrogel) for the treatment of osteonecrosis, a debilitating bone...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research focused on developing a cellular therapy approach to treat osteogenesis imperfecta (OI), a genetic disease that causes bone fragility. The $386,481 award to the University of Connecticut Health Center (UCHC) will fund a 5-year research project to evaluate different cell...
This Project Grant award of $404,187 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to explore the role of the Notch2 signaling pathway in the development of osteoarthritis and associated inflammatory responses. The University of Connecticut Health Center will conduct this research over a period of 5 years, with a goal of establishing the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $588,302 to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on the metabolic regulation of osteoclast differentiation and bone resorption. The key objectives are to: 1) establish the necessity and sufficiency of glutaminase (GLS) dependent...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to investigate factors influencing the development, progression, and healing of osteochondritis dissecans (OCD) lesions. The total award of $593,941 will support the Regents of the University of Minnesota in using porcine models to understand how the extent of vascular injury...
This Project Grant award of $1,469,862 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA Program 93.846 Arthritis, Musculoskeletal and Skin Diseases Research, will fund research to investigate the cellular and molecular mechanisms by which exercise controls bone quality. The primary awardee, The Regents of the University of California, San Francisco (UCSF), will lead this 5-year project focused on uncovering the role of osteocytes and...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...